The estimated Net Worth of Tony W Ho is at least $9.96 Миллион dollars as of 3 December 2021. Tony Ho owns over 26,667 units of CRISPR Therapeutics AG stock worth over $2,952,282 and over the last 7 years he sold CRSP stock worth over $1,007,007. In addition, he makes $6,005,550 as Executive Vice President - Research and Development at CRISPR Therapeutics AG.
Tony has made over 7 trades of the CRISPR Therapeutics AG stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 26,667 units of CRSP stock worth $1,211,748 on 3 December 2021.
The largest trade he's ever made was exercising 26,667 units of CRISPR Therapeutics AG stock on 3 December 2021 worth over $1,211,748. On average, Tony trades about 3,424 units every 29 days since 2017. As of 3 December 2021 he still owns at least 64,971 units of CRISPR Therapeutics AG stock.
You can see the complete history of Tony Ho stock trades at the bottom of the page.
Dr. Tony W. Ho M.D. serves as Executive Vice President - Research and Development of the Company. Prior to joining our company, Dr. Ho held a number of roles at AstraZeneca between 2012 and 2017, where he most recently was Senior Vice President and Head of Oncology Integration and Innovation. Before that, he was Vice President and Global Medicine Leader, where he led the development and commercialization of two key drugs for AstraZeneca – Lynparza, a PARP inhibitor for ovarian cancer and Imfinizi (anti-PD-L1), AstraZeneca’s first immuno-oncology drug for bladder cancer. Prior to joining AstraZeneca, Dr. Ho was the Neurology and Ophthalmology Clinical Section Head at Merck Research Laboratories, Merck & Co., Inc. Earlier in his career, Dr. Ho was the co-founder and Chief Scientific Officer of Neuronyx, Inc., a regenerative medicine company. Dr. Ho completed his B.S. in Electrical Engineering at the University of California, Los Angeles, and received his M.D. from the Johns Hopkins University School of Medicine.
As the Executive Vice President - Research and Development of CRISPR Therapeutics AG, the total compensation of Tony Ho at CRISPR Therapeutics AG is $6,005,550. There are 2 executives at CRISPR Therapeutics AG getting paid more, with Samarth Kulkarni having the highest compensation of $16,265,700.
Tony Ho is 54, he's been the Executive Vice President - Research and Development of CRISPR Therapeutics AG since 2017. There are 3 older and 9 younger executives at CRISPR Therapeutics AG. The oldest executive at CRISPR Therapeutics AG is Katherine High, 68, who is the Independent Director.
Tony's mailing address filed with the SEC is C/O ITEOS THERAPEUTICS, INC., 321 ARSENAL STREET, WATERTOWN, MA, 02472.
Over the last 8 years, insiders at CRISPR Therapeutics AG have traded over $284,003,967 worth of CRISPR Therapeutics AG stock and bought 3,347,446 units worth $53,410,590 . The most active insiders traders include Plc Gsk, Ali Behbahani и Corp /De/ Celgene. On average, CRISPR Therapeutics AG executives and independent directors trade stock every 13 days with the average trade being worth of $2,405,548. The most recent stock trade was executed by Julianne Bruno on 20 June 2024, trading 7,000 units of CRSP stock currently worth $318,080.
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Therapeutics AG executives and other stock owners filed with the SEC include: